Search Engine What we got wrong about GLP-1s
251 snips
Apr 10, 2026 
Dr. Rachel Bedard, a physician and public health writer with experience at Rikers Island and NYC homeless clinics, joins a lively conversation about how GLP-1 coverage missed the sickest patients. They dig into why these drugs became culturally untouchable, their surprising effects beyond weight loss, lingering side effects, and the class politics around who gets access.
AI Snips
Chapters
Transcript
Episode notes
Why Ozempic Became Both Medicine And Culture War
- Rachel Bedard says GLP-1s became a cultural flashpoint just as medicine discovered an unusually effective, apparently safe weight-loss drug with major diabetes benefits.
- By late 2023, she says these drugs showed all-cause mortality benefit, making the body-image discourse feel detached from their clinical importance.
The GLP One Debate Ignored Sick People
- Bedard argues media coverage centered affluent anxieties about thinness while ignoring people living with diabetes, amputations, dialysis, and high-risk obesity.
- She contrasts endless essays by "white lad[ies] who [don't] feel great about [their] weight" with drugs that could change U.S. mortality.
How GLP Ones Work Beyond Simple Appetite Control
- GLP-1s slow gastric emptying, increase satiety, and boost insulin release only when glucose is high, lowering blood sugar and weight.
- Bedard says their surprising effects on heart attacks, strokes, kidney disease, arthritis, heart failure, and addiction suggest obesity itself disrupts whole-body regulation.